Loading

Nivolumab (Opdivo®)

Dokument Fact Sheet
Spezifizierung Nierenzellkarzinom (Hypernephrom) » + Ipilimumab (Yervoy®) » fortgeschritten, Erstlinie, hohes Risiko
Stand Mai 2020
Dies ist die aktuell gültige Version des Dokuments

1Nivolumab + Ipilimumab, RCC, advanced, first line, high risk

1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/48 results for control, results for new therapy9 hazard ratio for new therapy19 International Metastatic Renal-Cell Carcinoma Database Consortium Score20 International Metastatic Renal-Cell Carcinoma Database Consortium Score

Kommentare